New pre-clinical data demonstrates a range of promising disease-modifying properties in Huntington’s disease for the CTX cell line, ReNeuron’s market leading stem cell programme for stroke disability. Pre-clinical data demonstrates the intracerebral transplantation of CTX cells into a rodent model of Huntington’s disease can lead to significant pathological and behavioural deficit improvements by both cell replacement and host cell regeneration mechanisms. Huntington’s disease is a genetic, prog ....
07 May 2020
New pre-clinical CTX cell line data shows added neurological potential
Sign up to access
Get access to our full offering from over 30 providers
Get access to our full offering from over 30 providers
New pre-clinical CTX cell line data shows added neurological potential
ReNeuron Group plc (RENE:LON) | 3.0 0 0.0% | Mkt Cap: 1.74m
- Published:
07 May 2020 -
Author:
Edward Thomason -
Pages:
3
New pre-clinical data demonstrates a range of promising disease-modifying properties in Huntington’s disease for the CTX cell line, ReNeuron’s market leading stem cell programme for stroke disability. Pre-clinical data demonstrates the intracerebral transplantation of CTX cells into a rodent model of Huntington’s disease can lead to significant pathological and behavioural deficit improvements by both cell replacement and host cell regeneration mechanisms. Huntington’s disease is a genetic, prog ....